UK 'value-based' pricing talks start next month
This article was originally published in Scrip
Executive Summary
Negotiations on the UK's new value-based pricing system are set to begin next month, a joint statement from the Association of the British Pharmaceutical Industry and England's Department of Health has confirmed. The industry association and the government will thrash out the landscape for drugs already on the market. They will also discuss whether value-based pricing will encompass oncology drugs that failed to pass muster with NICE, the health technology appraisal body for England and Wales. At present NICE-rejected oncology drugs can get a second chance for funding in England through the Cancer Drugs Fund.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.